Pulmonary Drugs Market

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Pulmonary Drugs Market contains market size and forecasts of Pulmonary Drugs in global, including the following market information:

Global Pulmonary Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Pulmonary Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Pulmonary Drugs companies in 2021 (%)

The global Pulmonary Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Inhaled Corticosteroids Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Pulmonary Drugs include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A and Alaxia SAS and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Pulmonary Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Pulmonary Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Pulmonary Drugs Market Segment Percentages, by Type, 2021 (%)

• Inhaled Corticosteroids
• Long Acting Beta-2 Agonists
• Antihistamines
• Vasodilators
• Others

Global Pulmonary Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Pulmonary Drugs Market Segment Percentages, by Application, 2021 (%)

• Asthma & COPD
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Cystic Fibrosis
• Others

Global Pulmonary Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Pulmonary Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Pulmonary Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Pulmonary Drugs revenues share in global market, 2021 (%)
• Key companies Pulmonary Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Pulmonary Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi SA
• Meda Pharmaceuticals
• Circassia Pharmaceuticals Plc.
• AstraZeneca Plc.
• GlaxoSmithKline Plc.
• Mallinckrodt Pharmaceuticals Plc.
• Cheisi Farmaceutici S.p.A
• Zambon Company S.p.A
• Alaxia SAS
• Merck Sharp & Dohme Limited